KMDA
Price
$6.85
Change
+$0.07 (+1.03%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
306.49M
68 days until earnings call
RDY
Price
$15.54
Change
+$0.01 (+0.06%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
12.48B
48 days until earnings call
Interact to see
Advertisement

KMDA vs RDY

Header iconKMDA vs RDY Comparison
Open Charts KMDA vs RDYBanner chart's image
Kamada
Price$6.85
Change+$0.07 (+1.03%)
Volume$6.35K
Capitalization306.49M
Dr. Reddy's Laboratories
Price$15.54
Change+$0.01 (+0.06%)
Volume$13.29K
Capitalization12.48B
KMDA vs RDY Comparison Chart
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. RDY commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and RDY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (KMDA: $6.77 vs. RDY: $15.53)
Brand notoriety: KMDA and RDY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: KMDA: 73% vs. RDY: 140%
Market capitalization -- KMDA: $306.49M vs. RDY: $12.48B
KMDA [@Pharmaceuticals: Other] is valued at $306.49M. RDY’s [@Pharmaceuticals: Other] market capitalization is $12.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • RDY’s FA Score: 1 green, 4 red.
According to our system of comparison, RDY is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 6 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).

  • KMDA’s TA Score: 6 bullish, 3 bearish.
  • RDY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than RDY.

Price Growth

KMDA (@Pharmaceuticals: Other) experienced а -1.46% price change this week, while RDY (@Pharmaceuticals: Other) price change was +5.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +79.53%. For the same industry, the average monthly price growth was +16.37%, and the average quarterly price growth was +68.04%.

Reported Earning Dates

KMDA is expected to report earnings on Aug 13, 2025.

RDY is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+79.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.5B) has a higher market cap than KMDA($306M). KMDA has higher P/E ratio than RDY: KMDA (37.43) vs RDY (19.68). KMDA YTD gains are higher at: 14.351 vs. RDY (-1.647). RDY has higher annual earnings (EBITDA): 84.9B vs. KMDA (22.4M). RDY has more cash in the bank: 72.4B vs. KMDA (55.6M). KMDA has less debt than RDY: KMDA (8.82M) vs RDY (19.9B). RDY has higher revenues than KMDA: RDY (271B) vs KMDA (143M).
KMDARDYKMDA / RDY
Capitalization306M12.5B2%
EBITDA22.4M84.9B0%
Gain YTD14.351-1.647-872%
P/E Ratio37.4319.68190%
Revenue143M271B0%
Total Cash55.6M72.4B0%
Total Debt8.82M19.9B0%
FUNDAMENTALS RATINGS
KMDA vs RDY: Fundamental Ratings
KMDA
RDY
OUTLOOK RATING
1..100
7525
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10028
SMR RATING
1..100
7846
PRICE GROWTH RATING
1..100
5047
P/E GROWTH RATING
1..100
4334
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (70) in the Biotechnology industry is in the same range as RDY (79) in the Pharmaceuticals Generic industry. This means that KMDA’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (28) in the Pharmaceuticals Generic industry is significantly better than the same rating for KMDA (100) in the Biotechnology industry. This means that RDY’s stock grew significantly faster than KMDA’s over the last 12 months.

RDY's SMR Rating (46) in the Pharmaceuticals Generic industry is in the same range as KMDA (78) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

RDY's Price Growth Rating (47) in the Pharmaceuticals Generic industry is in the same range as KMDA (50) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

RDY's P/E Growth Rating (34) in the Pharmaceuticals Generic industry is in the same range as KMDA (43) in the Biotechnology industry. This means that RDY’s stock grew similarly to KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDARDY
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
48%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
54%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 24 days ago
66%
Bullish Trend 2 days ago
51%
Declines
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 16 days ago
50%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
46%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
36%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSMAX11.44N/A
N/A
Hartford Small Cap Value A
OEGNX24.51N/A
N/A
Invesco Discovery Mid Cap Growth R
TCVYX22.49N/A
N/A
Touchstone Mid Cap Value Y
TSMEX14.42N/A
N/A
Nuveen Quant Small/Mid Cap Eq A
FAPNX13.03N/A
N/A
Fidelity Advisor Healthy Future Z

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+5.29%
COLL - RDY
32%
Poorly correlated
+0.34%
KMDA - RDY
29%
Poorly correlated
+1.65%
ZTS - RDY
27%
Poorly correlated
+0.01%
AMPH - RDY
27%
Poorly correlated
-1.31%
TAK - RDY
25%
Poorly correlated
-0.27%
More